CoChat

Adeno-associated Virus as a Mammalian DNA Vector

Open access
Salganik, Max, Hirsch, Matthew L., Samulski, Richard Jude · 2015 · Microbiology Spectrum
Cited by 87

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Abstract

In the nearly five decades since its accidental discovery, adeno-associated virus (AAV) has emerged as a highly versatile vector system for both research and clinical applications. A broad range of natural serotypes, as well as an increasing number of capsid variants, has combined to produce a repertoire of vectors with different tissue tropisms, immunogenic profiles and transduction efficiencies. The story of AAV is one of continued progress and surprising discoveries in a viral system that, at first glance, is deceptively simple. This apparent simplicity has enabled the advancement of AAV into the clinic, where despite some challenges it has provided hope for patients and a promising new tool for physicians. Although a great deal of work remains to be done, both in studying the basic biology of AAV and in optimizing its clinical application, AAV vectors are currently the safest and most efficient platform for gene transfer in mammalian cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/microbiolspec.mdna3-0052-2014

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 86 references

Research works printed but not linked: 150

  1. Atchison RW Casto BC Hammon WM. 1965. Adenovirus-associated defective virus particles. Science 149: 754–756. [PubMed][CrossRef] · DOI · Paper page
  2. Rose JA Berns KI Hoggan MD Koczot FJ. 1969. Evidence for a single-stranded adenovirus-associated virus genome: formation of a DNA density hybrid on release of viral DNA. Proc Natl Acad Sci USA 64: 863–869. [PubMed][CrossRef] · DOI · Paper page
  3. Zhong L Zhou X Li Y Qing K Xiao X Samulski RJ Srivastava A. 2008. Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo : mechanism of transduction. Mol Ther 16: 290–295. [PubMed][CrossRef] · DOI · Paper page
  4. Kotin RM Siniscalco M Samulski RJ Zhu XD Hunter L Laughlin CA McLaughlin S Muzyczka N Rocchi M Berns KI. 1990. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87: 2211–2215. [PubMed][CrossRef] · DOI · Paper page
  5. Samulski RJ Zhu X Xiao X Brook JD Housman DE Epstein N Hunter LA. 1991. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10: 3941–3950. [PubMed] · DOI · Paper page
  6. Linden RM Ward P Giraud C Winocour E Berns KI. 1996. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 93: 11288–11294. [PubMed][CrossRef] · DOI · Paper page
  7. Mitchell AM Nicolson SC Warischalk JK Samulski RJ. 2010. AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther 10: 319–340. [PubMed][CrossRef] · DOI · Paper page
  8. Young SM Mccarty DM Degtyareva N Samulski RJ. 2000. Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol 74: 3953–3966. [PubMed][CrossRef] · DOI · Paper page
  9. Opie SR Warrington KH Agbandje-McKenna M Zolotukhin S Muzyczka N. 2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77: 6995–7006. [PubMed][CrossRef] · DOI · Paper page
  10. Gurda BL Raupp C Popa-Wagner R Naumer M Olson NH Ng R McKenna R Baker TS Kleinschmidt JA Agbandje-McKenna M. 2012. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J Virol 86: 7739–7751. [PubMed][CrossRef] · DOI · Paper page
  11. Muzyczka N. 1992. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 158: 97–129. [PubMed][CrossRef] · DOI · Paper page
  12. Rolling F Samulski RJ. 1995. AAV as a viral vector for human gene therapy. Generation of recombinant virus. Mol Biotechnol 3: 9–15. [PubMed][CrossRef] · DOI
  13. DiMattia M Govindasamy L Levy HC Gurda-Whitaker B Kalina A Kohlbrenner E Chiorini JA McKenna R Muzyczka N Zolotukhin S Agbandje-McKenna M. 2005. Production purification crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 5. Acta Crystallogr Sect F Struct Biol Cryst Commun 61: 917–921. [PubMed][CrossRef] · DOI · Paper page
  14. Xie Q Ongley HM Hare J Chapman MS. 2008. Crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 6. Acta Crystallogr Sect F Struct Biol Cryst Commun 64: 1074–1078. [PubMed][CrossRef] · DOI
  15. Padron E Bowman V Kaludov N Govindasamy L Levy H Nick P McKenna R Muzyczka N Chiorini JA Baker TS Agbandje-McKenna M. 2005. Structure of adeno-associated virus type 4. J Virol 79: 5047–5058. [PubMed][CrossRef] · DOI · Paper page
  16. Kaludov N Padron E Govindasamy L McKenna R Chiorini JA Agbandje-McKenna M. 2003. Production purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 4. Virology 306: 1–6. [PubMed][CrossRef] · DOI
  17. Nam H-J Lane MD Padron E Gurda B McKenna R Kohlbrenner E Aslanidi G Byrne B Muzyczka N Zolotukhin S Agbandje-McKenna M. 2007. Structure of adeno-associated virus serotype 8 a gene therapy vector. J Virol 81: 12260–12271. [PubMed][CrossRef] · DOI · Paper page
  18. Lerch TF Xie Q Ongley HM Hare J Chapman MS. 2009. Twinned crystals of adeno-associated virus serotype 3b prove suitable for structural studies. Acta Crystallogr Sect F Struct Biol Cryst Commun 65: 177–183. [PubMed][CrossRef] · DOI
  19. Mitchell M Nam H-J Carter A McCall A Rence C Bennett A Gurda B McKenna R Porter M Sakai Y Byrne BJ Muzyczka N Aslanidi G Zolotukhin S Agbandje-McKenna M. 2009. Production purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 9. Acta Crystallogr Sect F Struct Biol Cryst Commun 65: 715–718. [PubMed][CrossRef] · DOI · Paper page
  20. Miller EB Gurda-Whitaker B Govindasamy L McKenna R Zolotukhin S Muzyczka N Agbandje-McKenna M. 2006. Production purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1. Acta Crystallogr Sect F Struct Biol Cryst Commun 62: 1271–1274. [PubMed][CrossRef] · DOI · Paper page
  21. Quesada O Gurda B Govindasamy L McKenna R Kohlbrenner E Aslanidi G Zolotukhin S Muzyczka N Agbandje-McKenna M. 2007. Production purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 7. Acta Crystallogr Sect F Struct Biol Cryst Commun 63: 1073–1076. [PubMed][CrossRef] · DOI · Paper page
  22. Lane MD Nam H-J Padron E Gurda-Whitaker B Kohlbrenner E Aslanidi G Byrne B McKenna R Muzyczka N Zolotukhin S Agbandje-McKenna M. 2005. Production purification crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8. Acta Crystallogr Sect F Struct Biol Cryst Commun 61: 558–561. [PubMed][CrossRef] · DOI
  23. O'Donnell J Taylor KA Chapman MS. 2009. Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex. Virology 385: 434–443. [PubMed][CrossRef] · DOI · Paper page
  24. Lerch TF Xie Q Chapman MS. 2010. The structure of adeno-associated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion. Virology 403: 26–36. [PubMed][CrossRef] · DOI · Paper page
  25. Ng R Govindasamy L Gurda BL McKenna R Kozyreva OG Samulski RJ Parent KN Baker TS Agbandje-McKenna M. 2010. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol 84: 12945–12957. [PubMed][CrossRef] · DOI · Paper page
  26. Rabinowitz JE Bowles DE Faust SM Ledford JG Cunningham SE Samulski RJ. 2004. Cross-dressing the virion : the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol 78: 4421–4432. [PubMed][CrossRef] · DOI · Paper page
  27. Cavalier-Smith T. 1974. Palindromic base sequences and replication of eukaryote chromosome ends. Nature 250: 467–470. [PubMed][CrossRef] · DOI · Paper page
  28. Snyder RO Im DS Ni T Xiao X Samulski RJ Muzyczka N. 1993. Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein. J Virol 67: 6096–6104. [PubMed] · DOI · Paper page
  29. Chiorini JA Wiener SM Owens RA Kyöstiö SR Kotin RM Safer B. 1994. Sequence requirements for stable binding and function of Rep68 on the adeno-associated virus type 2 inverted terminal repeats. J Virol 68: 7448–7457. [PubMed] · DOI · Paper page
  30. Mccarty DM Pereira DJ Zolotukhin I Zhou X Ryan JH Muzyczka N. 1994. Identification of linear DNA sequences that specifically bind the adeno-associated virus Rep protein. J Virol 68: 4988–4997. [PubMed] · DOI · Paper page
  31. Mccarty DM Ryan JH Zolotukhin S Zhou X Muzyczka N. 1994. Interaction of the adeno-associated virus Rep protein with a sequence within the A palindrome of the viral terminal repeat. J Virol 68: 4998–5006. [PubMed] · DOI · Paper page
  32. Weitzman MD Kyöstiö SR Kotin RM Owens RA. 1994. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 91: 5808–5812. [PubMed][CrossRef] · DOI · Paper page
  33. Straus SE Sebring ED Rose JA. 1976. Concatemers of alternating plus and minus strands are intermediates in adenovirus-associated virus DNA synthesis. Proc Natl Acad Sci USA 73: 742–746. [PubMed][CrossRef] · DOI · Paper page
  34. Lusby E Bohenzky R Berns KI. 1981. Inverted terminal repetition in adeno-associated virus DNA: independence of the orientation at either end of the genome. J Virol 37: 1083–1086. [PubMed] · DOI · Paper page
  35. Snyder RO Im DS Muzyczka N. 1990. Evidence for covalent attachment of the adeno-associated virus (AAV) rep protein to the ends of the AAV genome. J Virol 64: 6204–6213. [PubMed] · DOI · Paper page
  36. Im DS Muzyczka N. 1990. The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell 61: 447–457. [PubMed][CrossRef] · DOI · Paper page
  37. Owens RA Weitzman MD Kyöstiö SR Carter BJ. 1993. Identification of a DNA-binding domain in the amino terminus of adeno-associated virus Rep proteins. J Virol 67: 997–1005. [PubMed] · DOI · Paper page
  38. Chiorini JA Weitzman MD Owens RA Urcelay E Safer B Kotin RM. 1994. Biologically active Rep proteins of adeno-associated virus type 2 produced as fusion proteins in Escherichia coli. J Virol 68: 797–804. [PubMed] · DOI · Paper page
  39. Brister JR Muzyczka N. 1999. Rep-mediated nicking of the adeno-associated virus origin requires two biochemical activities DNA helicase activity and transesterification. J Virol 73: 9325–9336. [PubMed] · DOI · Paper page
  40. Wonderling RS Kyöstiö SR Owens RA. 1995. A maltose-binding protein/adeno-associated virus Rep68 fusion protein has DNA–RNA helicase and ATPase activities. J Virol 69: 3542–3548. [PubMed] · DOI · Paper page
  41. Snyder RO Samulski RJ Muzyczka N. 1990. In vitro resolution of covalently joined AAV chromosome ends. Cell 60: 105–113. [PubMed][CrossRef] · DOI · Paper page
  42. Hermonat PL Labow MA Wright R Berns KI Muzyczka N. 1984. Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol 51: 329–339. [PubMed] · DOI · Paper page
  43. Samulski RJ Chang LS Shenk T. 1989. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 63: 3822–3828. [PubMed] · DOI · Paper page
  44. Ferrari FK Xiao X McCarty D Samulski RJ. 1997. New developments in the generation of Ad-free high-titer rAAV gene therapy vectors. Nat Med 3: 1295–1297. [PubMed][CrossRef] · DOI
  45. Grieger JC Samulski RJ. 2012. Adeno-associated virus vectorology manufacturing and clinical applications. Meth Enzymol 507: 229–254. [PubMed][CrossRef] · DOI · Paper page
  46. Fisher KJ Gao GP Weitzman MD DeMatteo R Burda JF Wilson JM. 1996. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 70: 520–532. [PubMed] · DOI · Paper page
  47. Wu Z Miller E Agbandje-McKenna M Samulski RJ. 2006. Alpha2 3 and alpha2 6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol 80: 9093–9103. [PubMed][CrossRef] · DOI · Paper page
  48. Summerford C Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438–1445. [PubMed] · DOI · Paper page
  49. Kaludov N Brown KE Walters RW Zabner J Chiorini JA. 2001. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 75: 6884–6893. [PubMed][CrossRef] · DOI · Paper page
  50. Walters RW Yi SM Keshavjee S Brown KE Welsh MJ Chiorini JA Zabner J. 2001. Binding of adeno-associated virus type 5 to 2 3-linked sialic acid is required for gene transfer. J Biol Chem 276: 20610–20616. [PubMed][CrossRef] · DOI · Paper page
  51. Shen S Bryant KD Brown SM Randell SH Asokan A. 2011. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286: 13532–13540. [PubMed][CrossRef] · DOI · Paper page
  52. Müller OJ Leuchs B Pleger ST Grimm D Franz W-M Katus HA Kleinschmidt JA. 2006. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 70: 70–78. [PubMed][CrossRef] · DOI · Paper page
  53. Asokan A Conway JC Phillips JL Li C Hegge J Sinnott R Yadav S DiPrimio N Nam H-J Agbandje-McKenna M McPhee S Wolff J Samulski RJ. 2010. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 28: 79–82. [PubMed][CrossRef] · DOI · Paper page
  54. Shen S Horowitz ED Troupes AN Brown SM Pulicherla N Samulski RJ Agbandje-McKenna M Asokan A. 2013. Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J Biol Chem 288: 28814–28823. [PubMed][CrossRef] · DOI · Paper page
  55. Yang Q Mamounas M Yu G Kennedy S Leaker B Merson J Wong-Staal F Yu M Barber JR. 1998. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Human Gene Ther 9: 1929–1937. [PubMed][CrossRef] · DOI · Paper page
  56. Grifman M Trepel M Speece P Gilbert LB Arap W Pasqualini R Weitzman MD. 2001. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 3: 964–975. [PubMed][CrossRef] · DOI · Paper page
  57. Loiler SA Conlon TJ Song S Tang Q Warrington KH Agarwal A Kapturczak M Li C Ricordi C Atkinson MA Muzyczka N Flotte TR. 2003. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther 10: 1551–1558. [PubMed][CrossRef] · DOI
  58. Shi W Arnold GS Bartlett JS. 2001. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 12: 1697–1711. [PubMed][CrossRef] · DOI · Paper page
  59. Müller OJ Kaul F Weitzman MD Pasqualini R Arap W Kleinschmidt JA Trepel M. 2003. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21: 1040–1046. [PubMed][CrossRef] · DOI · Paper page
  60. Judd J Wei F Nguyen PQ Tartaglia LJ Agbandje-McKenna M Silberg JJ Suh J. 2012. Random insertion of mCherry into VP3 domain of adeno-associated virus yields fluorescent capsids with no loss of infectivity. Mol Ther Nucleic Acids 1: e54. [PubMed][CrossRef] · DOI · Paper page
  61. Salganik M Venkatakrishnan B Bennett A Lins B Yarbrough J Muzyczka N Agbandje-McKenna M McKenna R. 2012. Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J Virol 86: 11877–11885. [PubMed][CrossRef] · DOI · Paper page
  62. Münch RC Janicki H Völker I Rasbach A Hallek M Büning H Buchholz CJ. 2013. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther 21: 109–118. [PubMed][CrossRef] · DOI · Paper page
  63. Sonntag F Bleker S Leuchs B Fischer R Kleinschmidt JA. 2006. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 80: 11040–11054. [PubMed][CrossRef] · DOI · Paper page
  64. White AF Mazur M Sorscher EJ Zinn KR Ponnazhagan S. 2008. Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells. Hum Gene Ther 19: 1407–1414. [PubMed][CrossRef] · DOI
  65. Nicklin SA Buening H Dishart KL de Alwis M Girod A Hacker U Thrasher AJ Ali RR Hallek M Baker AH. 2001. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 4: 174–181. [PubMed][CrossRef] · DOI · Paper page
  66. White SJ Nicklin SA Büning H Brosnan MJ Leike K Papadakis ED Hallek M Baker AH. 2004. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 109: 513–519. [PubMed][CrossRef] · DOI · Paper page
  67. Work LM Büning H Hunt E Nicklin SA Denby L Britton N Leike K Odenthal M Drebber U Hallek M Baker AH. 2006. Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther 13: 683–693. [PubMed][CrossRef] · DOI · Paper page
  68. Yu C-Y Yuan Z Cao Z Wang B Qiao C Li J Xiao X. 2009. A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther 16: 953–962. [PubMed][CrossRef] · DOI · Paper page
  69. Perabo L Büning H Kofler DM Ried MU Girod A Wendtner CM Enssle J Hallek M. 2003. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 8: 151–157. [PubMed][CrossRef] · DOI · Paper page
  70. Waterkamp DA Müller OJ Ying Y Trepel M Kleinschmidt JA. 2006. Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med 8: 1307–1319. [PubMed][CrossRef] · DOI · Paper page
  71. Michelfelder S Lee M-K deLima-Hahn E Wilmes T Kaul F Müller O Kleinschmidt JA Trepel M. 2007. Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol 35: 1766–1776. [PubMed][CrossRef] · DOI
  72. Michelfelder S Kohlschütter J Skorupa A Pfennings S Müller O Kleinschmidt JA Trepel M. 2009. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS ONE 4: e5122. [PubMed][CrossRef] · DOI · Paper page
  73. Popa-Wagner R Porwal M Kann M Reuss M Weimer M Florin L Kleinschmidt JA. 2012. Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J Virol 86: 9163–9174. [PubMed][CrossRef] · DOI · Paper page
  74. Johnson JS Li C DiPrimio N Weinberg MS McCown TJ Samulski RJ. 2010. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol 84: 8888–8902. [PubMed][CrossRef] · DOI · Paper page
  75. Maguire CA Gianni D Meijer DH Shaket LA Wakimoto H Rabkin SD Gao G Sena-Esteves M. 2010. Directed evolution of adeno-associated virus for glioma cell transduction. J Neurooncol 96: 337–347. [PubMed][CrossRef] · DOI · Paper page
  76. Ward P Walsh CE. 2009. Chimeric AAV Cap sequences alter gene transduction. Virology 386: 237–248. [PubMed][CrossRef] · DOI
  77. Farr GA Zhang L-G Tattersall P. 2005. Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry. Proc Natl Acad Sci USA 102: 17148–17153. [PubMed][CrossRef] · DOI · Paper page
  78. Yang L Jiang J Drouin LM Agbandje-McKenna M Chen C Qiao C Pu D Hu X Wang D-Z Li J Xiao X. 2009. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA 106: 3946–3951. [PubMed][CrossRef] · DOI · Paper page
  79. Mani B Baltzer C Valle N Almendral JM Kempf C Ros C. 2006. Low pH-dependent endosomal processing of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal sequence (N-VP1) N-VP2 cleavage and uncoating of the full-length genome. J Virol 80: 1015–1024. [PubMed][CrossRef] · DOI
  80. Cohen S Marr AK Garcin P Panté N. 2011. Nuclear envelope disruption involving host caspases plays a role in the parvovirus replication cycle. J Virol 85: 4863–4874. [PubMed][CrossRef] · DOI
  81. Xiao P-J Samulski RJ. 2012. Cytoplasmic trafficking endosomal escape and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol 86: 10462–10473. [PubMed][CrossRef] · DOI · Paper page
  82. Duan D Li Q Kao AW Yue Y Pessin JE Engelhardt JF. 1999. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 73: 10371–10376. [PubMed] · DOI · Paper page
  83. Uhrig S Coutelle O Wiehe T Perabo L Hallek M Büning H. 2012. Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther 19: 210–218. [PubMed][CrossRef] · DOI
  84. Liu Y Joo K-I Wang P. 2012. Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther 20: 308–317. [PubMed][CrossRef] · DOI
  85. Bantel-Schaal U Braspenning-Wesch I Kartenbeck J. 2009. Adeno-associated virus type 5 exploits two different entry pathways in human embryo fibroblasts. J Gen Virol 90: 317–322. [PubMed][CrossRef] · DOI · Paper page
  86. Nonnenmacher M Weber T. 2011. Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 10: 563–576. [PubMed][CrossRef] · DOI · Paper page
  87. Nicolson SC Samulski RJ. 2014. Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J Virol 88: 4132–4144. [PubMed][CrossRef] · DOI · Paper page
  88. Johnson JS Samulski RJ. 2009. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol 83: 2632–2644. [PubMed][CrossRef] · DOI · Paper page
  89. Salganik M Aydemir F Nam H-J McKenna R Agbandje-McKenna M Muzyczka N. 2014. Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J Virol 88: 1071–1079. [PubMed][CrossRef] · DOI · Paper page
  90. Ding W Zhang LN Yeaman C Engelhardt JF. 2006. rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion. Mol Ther 13: 671–682. [PubMed][CrossRef] · DOI · Paper page
  91. Hauck B Zhao W High K Xiao W. 2004. Intracellular viral processing not single-stranded DNA accumulation is crucial for recombinant adeno-associated virus transduction. J Virol 78: 13678–13686. [PubMed][CrossRef] · DOI · Paper page
  92. Hauswirth WW Berns KI. 1979. Adeno-associated virus DNA replication: nonunit-length molecules. Virology 93: 57–68. [PubMed][CrossRef] · DOI
  93. Ni TH McDonald WF Zolotukhin I Melendy T Waga S Stillman B Muzyczka N. 1998. Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J Virol 72: 2777–2787. [PubMed] · DOI · Paper page
  94. Nash K Chen W McDonald WF Zhou X Muzyczka N. 2007. Purification of host cell enzymes involved in adeno-associated virus DNA replication. J Virol 81: 5777–5787. [PubMed][CrossRef] · DOI · Paper page
  95. Song S Laipis PJ Berns KI Flotte TR. 2001. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci USA 98: 4084–4088. [PubMed][CrossRef] · DOI · Paper page
  96. Inagaki K Ma C Storm TA Kay MA Nakai H. 2007. The role of DNA-PKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol 81: 11304–11321. [PubMed][CrossRef] · DOI · Paper page
  97. Xiao X Li J Samulski RJ. 1996. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70: 8098–8108. [PubMed] · DOI · Paper page
  98. Sanlioglu S Duan D Engelhardt JF. 1999. Two independent molecular pathways for recombinant adeno-associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction. Hum Gene Ther 10: 591–602. [PubMed][CrossRef] · DOI · Paper page
  99. Zentilin L Marcello A Giacca M. 2001. Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol 75: 12279–12287. [PubMed][CrossRef] · DOI · Paper page
  100. Russell DW Alexander IE Miller AD. 1995. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA 92: 5719–5723. [PubMed][CrossRef] · DOI · Paper page
  101. Miller JL Donahue RE Sellers SE Samulski RJ Young NS Nienhuis AW. 1994. Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad Sci USA 91: 10183–10187. [PubMed][CrossRef] · DOI · Paper page
  102. Rahman SH Bobis-Wozowicz S Chatterjee D Gellhaus K Pars K Heilbronn R Jacobs R Cathomen T. 2013. The nontoxic cell cycle modulator indirubin augments transduction of adeno-associated viral vectors and zinc-finger nuclease-mediated gene targeting. Hum Gene Ther 24: 67–77. [PubMed][CrossRef] · DOI · Paper page
  103. Winocour E Callaham MF Huberman E. 1988. Perturbation of the cell cycle by adeno-associated virus. Virology 167: 393–399. [PubMed][CrossRef] · DOI
  104. Fragkos M Beard P. 2011. Mitotic catastrophe occurs in the absence of apoptosis in p53-null cells with a defective G1 checkpoint. PLoS ONE 6: e22946. [PubMed][CrossRef] · DOI
  105. Fragkos M Jurvansuu J Beard P. 2009. H2AX is required for cell cycle arrest via the p53/p21 pathway. Mol Cell Biol 29: 2828–2840. [PubMed][CrossRef] · DOI · Paper page
  106. Miao CH Snyder RO Schowalter DB Patijn GA Donahue B Winther B Kay MA. 1998. The kinetics of rAAV integration in the liver. Nat Genet 19: 13–15. [PubMed][CrossRef] · DOI · Paper page
  107. Yang CC Xiao X Zhu X Ansardi DC Epstein ND Frey MR Matera AG Samulski RJ. 1997. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro . J Virol 71: 9231–9247. [PubMed] · DOI · Paper page
  108. Miller DG Trobridge GD Petek LM Jacobs MA Kaul R Russell DW. 2005. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol 79: 11434–11442. [PubMed][CrossRef] · DOI · Paper page
  109. Flotte TR Afione SA Zeitlin PL. 1994. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 11: 517–521. [PubMed][CrossRef] · DOI · Paper page
  110. Xiao X Xiao W Li J Samulski RJ. 1997. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol 71: 941–948. [PubMed] · DOI · Paper page
  111. Hirsch ML Agbandje-McKenna M Samulski RJ. 2010. Little vector big gene transduction : fragmented genome reassembly of adeno-associated virus. Mol Ther 18: 6–8. [PubMed][CrossRef] · DOI · Paper page
  112. Lai Y Zhao J Yue Y Wasala NB Duan D. 2014. Partial restoration of cardiac function with ΔPDZ nNOS in aged mdx model of Duchenne cardiomyopathy. Hum Mol Genet 23: 3189–3199. [PubMed][CrossRef] · DOI
  113. Russell DW Hirata RK. 1998. Human gene targeting by viral vectors. Nat Genet 18: 325–330. [PubMed][CrossRef] · DOI · Paper page
  114. Smithies O Gregg RG Boggs SS Koralewski MA Kucherlapati RS. 1985. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 317: 230–234. [PubMed][CrossRef] · DOI · Paper page
  115. Thomas KR Capecchi MR. 1987. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51: 503–512. [PubMed][CrossRef] · DOI · Paper page
  116. Russell DW Hirata RK. 2008. Human gene targeting favors insertions over deletions. Hum Gene Ther 19: 907–914. [CrossRef] · DOI
  117. Vasileva A Linden RM Jessberger R. 2006. Homologous recombination is required for AAV-mediated gene targeting. Nucleic Acids Res 34: 3345–3360. [PubMed][CrossRef] · DOI · Paper page
  118. Trobridge G Hirata RK Russell DW. 2005. Gene targeting by adeno-associated virus vectors is cell-cycle dependent. Hum Gene Ther 16: 522–526. [PubMed][CrossRef] · DOI
  119. Petek LM Fleckman P Miller DG. 2010. Efficient KRT14 targeting and functional characterization of transplanted human keratinocytes for the treatment of epidermolysis bullosa simplex. Mol Ther 18: 1624–1632. [PubMed][CrossRef] · DOI
  120. Paulk NK Wursthorn K Haft A Pelz C Clarke G Newell AH Olson SB Harding CO Finegold MJ Bateman RL Witte JF McClard R Grompe M. 2012. In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice. Mol Ther 20: 1981–1987. [PubMed][CrossRef] · DOI
  121. Mueller C Flotte TR. 2008. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15: 858–863. [PubMed][CrossRef] · DOI · Paper page
  122. Rabinowitz JE Rolling F Li C Conrath H Xiao W Xiao X Samulski RJ. 2002. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76: 791–801. [PubMed][CrossRef] · DOI · Paper page
  123. Podsakoff G Wong KK Chatterjee S. 1994. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 68: 5656–5666. [PubMed] · DOI · Paper page
  124. Berns KI Pinkerton TC Thomas GF Hoggan MD. 1975. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 68: 556–560. [PubMed][CrossRef] · DOI
  125. Tenenbaum L Lehtonen E Monahan PE. 2003. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 3: 545–565. [PubMed][CrossRef] · DOI · Paper page
  126. Testa F Maguire AM Rossi S Pierce EA Melillo P Marshall K Banfi S Surace EM Sun J Acerra C Wright JF Wellman J High KA Auricchio A Bennett J Simonelli F. 2013. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 120: 1283–1291. [PubMed][CrossRef] · DOI · Paper page
  127. Bennett J Ashtari M Wellman J Marshall KA Cyckowski LL Chung DC McCague S Pierce EA Chen Y Bennicelli JL Zhu X Ying G-S Sun J Wright JF Auricchio A Simonelli F Shindler KS Mingozzi F High KA Maguire AM. 2012. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 4: 120ra15. [PubMed][CrossRef] · DOI · Paper page
  128. Hajjar RJ Zsebo K Deckelbaum L Thompson C Rudy J Yaroshinsky A Ly H Kawase Y Wagner K Borow K Jaski B London B Greenberg B Pauly DF Patten R Starling R Mancini D Jessup M. 2008. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 14: 355–367. [PubMed][CrossRef] · DOI · Paper page
  129. Jacobson SG Cideciyan AV Ratnakaram R Heon E Schwartz SB Roman AJ Peden MC Aleman TS Boye SL Sumaroka A Conlon TJ Calcedo R Pang J-J Erger KE Olivares MB Mullins CL Swider M Kaushal S Feuer WJ Iannaccone A Fishman GA Stone EM Byrne BJ Hauswirth WW. 2012. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130: 9–24. [PubMed][CrossRef] · DOI · Paper page
  130. Ross CJD Twisk J Bakker AC Miao F Verbart D Rip J Godbey T Dijkhuizen P Hermens WTJMC Kastelein JJP Kuivenhoven JA Meulenberg JM Hayden MR. 2006. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther 17: 487–499. [PubMed][CrossRef] · DOI · Paper page
  131. Chuah M VandenDriessche T. 2007. Gene therapy for hemophilia “A” and “B”: efficacy safety and immune consequences. Verh K Acad Geneeskd Belg 69: 315–334. [PubMed]
  132. Chen J Wu Q Yang P Hsu H-C Mountz JD. 2006. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy. Mol Ther 13: 260–269. [PubMed][CrossRef] · DOI · Paper page
  133. Li C Hirsch M Asokan A Zeithaml B Ma H Kafri T Samulski RJ. 2007. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo . J Virol 81: 7540–7547. [PubMed][CrossRef] · DOI · Paper page
  134. Li H Murphy SL Giles-Davis W Edmonson S Xiang Z Li Y Lasaro MO High KA Ertl HC. 2007. Pre-existing AAV capsid-specific CD8 + T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 15: 792–800. [PubMed][CrossRef] · DOI · Paper page
  135. Wang Z Allen JM Riddell SR Gregorevic P Storb R Tapscott SJ Chamberlain JS Kuhr CS. 2007. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 18: 18–26. [PubMed][CrossRef] · DOI · Paper page
  136. Gao G-P Alvira MR Wang L Calcedo R Johnston J Wilson JM. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854–11859. [PubMed][CrossRef] · DOI · Paper page
  137. Li C Narkbunnam N Samulski RJ Asokan A Hu G Jacobson LJ Manco-Johnson MJ Monahan PE Joint Outcome Study Investigators. 2012. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther 19: 288–294. [PubMed][CrossRef] · DOI · Paper page
  138. Carlisle RC Benjamin R Briggs SS Sumner-Jones S McIntosh J Gill D Hyde S Nathwani A Subr V Ulbrich K Seymour LW Fisher KD. 2008. Coating of adeno-associated virus with reactive polymers can ablate virus tropism enable retargeting and provide resistance to neutralising antisera. J Gene Med 10: 400–411. [PubMed][CrossRef] · DOI · Paper page
  139. Georg-Fries B Biederlack S Wolf J Hausen zur H. 1984. Analysis of proteins helper dependence and seroepidemiology of a new human parvovirus. Virology 134: 64–71. [CrossRef] · DOI · Paper page
  140. Jacobson EM Huber A Tomer Y. 2008. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun 30: 58–62. [PubMed][CrossRef] · DOI · Paper page
  141. Taneja V David CS. 2001. Lessons from animal models for human autoimmune diseases. Nat Immunol 2: 781–784. [PubMed][CrossRef] · DOI
  142. Erles K Sebökovà P Schlehofer JR. 1999. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 59: 406–411. [CrossRef] · DOI · Paper page
  143. Grewal IS Flavell RA. 1998. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16: 111–135. [PubMed][CrossRef] · DOI · Paper page
  144. Nathwani AC Gray JT McIntosh J Ng CYC Zhou J Spence Y Cochrane M Gray E Tuddenham EGD Davidoff AM. 2007. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109: 1414–1421. [PubMed][CrossRef] · DOI · Paper page
  145. Chen S Kapturczak M Loiler SA Zolotukhin S Glushakova OY Madsen KM Samulski RJ Hauswirth WW Campbell-Thompson M Berns KI Flotte TR Atkinson MA Tisher CC Agarwal A. 2005. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther 16: 235–247. [PubMed][CrossRef] · DOI · Paper page
  146. Summerford C Bartlett JS Samulski RJ. 1999. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 5: 78–82. [PubMed] · DOI · Paper page
  147. Akache B Grimm D Pandey K Yant SR Xu H Kay MA. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8 2 3 and 9. J Virol 80: 9831–9836. [PubMed][CrossRef] · DOI · Paper page
  148. Ling C Lu Y Kalsi JK Jayandharan GR Li B Ma W Cheng B Gee SWY McGoogan KE Govindasamy L Zhong L Agbandje-McKenna M Srivastava A. 2010. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther 21: 1741–1747. [PubMed][CrossRef] · DOI · Paper page
  149. Wu Z Asokan A Grieger JC Govindasamy L Agbandje-McKenna M Samulski RJ. 2006. Single amino acid changes can influence titer heparin binding and tissue tropism in different adeno-associated virus serotypes. J Virol 80: 11393–11397. [PubMed][CrossRef] · DOI · Paper page
  150. Weller ML Amornphimoltham P Schmidt M Wilson PA Gutkind JS Chiorini JA. 2010. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med 16: 662–664. [PubMed][CrossRef] · DOI · Paper page

Cited by

See all 87

Metadata

Authors
Salganik, M., Hirsch, M. L., & Samulski, R. J.
Venue
Microbiology Spectrum
Published
2015-07-02
Volume
3
Issue
4
ISSN
2165-0497 (ISSN-L)
OpenAlex
W876571388
Cited by
87
References
86
FWCI
5.14
Type
journal article
Language
en
Open access
green
Licence
journals.asm.org/non-commercial-tdm-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adeno-associated Virus as a Mammalian DNA Vector. https://app.cochat.ai/papers/10.1128/microbiolspec.mdna3-0052-2014
The paper
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015). Adeno-associated Virus as a Mammalian DNA Vector. Microbiology Spectrum. https://doi.org/10.1128/microbiolspec.mdna3-0052-2014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.